CJC1295 & Ipamorelin 20 Pen

Ipamorelin CJC-1295 is a dual research peptide formulation combining Ipamorelin, a selective ghrelin-receptor agonist (GHSR-1a), and CJC-1295, a long-acting synthetic analogue of growth hormone-releasing hormone (GHRH). Both compounds are studied for their roles in growth hormone axis research. BodyPharm supplies this formulation strictly for laboratory research purposes.

BodyPharm sells Ipamorelin CJC-1295 strictly for research purposes. Customers are responsible for understanding applicable regulations in their jurisdiction.

Preclinical studies indicate that Ipamorelin stimulates pulsatile growth hormone release with high selectivity and minimal cortisol or prolactin elevation compared to earlier secretagogues. Research on CJC-1295 with DAC technology suggests an extended plasma half-life suitable for long-duration GH axis studies. Combined administration has been documented to produce significant IGF-1 elevation in rodent models.

Studies indicate that CJC-1295 and Ipamorelin act through distinct but complementary receptor pathways. CJC-1295 acts via the GHRH receptor and Ipamorelin via GHSR-1a. Research suggests this dual stimulation may amplify GH pulsatility, making the combination a useful tool for studying the somatotropic axis in laboratory models.

BodyPharm is a UAE-based research peptide supplier offering Ipamorelin CJC-1295 for laboratory use with same-day delivery across Dubai, Abu Dhabi, and the wider UAE. Each batch is independently verified at 99% or higher purity by Janoshik analytical laboratory.